24 July 2026
Dentons advises Biofarm and its majority shareholders on landmark acquisition by Polpharma through voluntary public takeover offer
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Loredana Chitu Lead | Dentons | Partner | M&A | Bucharest |
| Kamran Pirani Lead | Dentons | Partner | M&A | Budapest |
| Brigitta Kovács | Dentons | Associate | Not stated | Budapest |
| Abbey Varns | Dentons | Associate | Not stated | Prague |
| Alin Roca | Dentons | Senior associate | Not stated | Bucharest |
| Bogdan Galatanu | Dentons | Associate | Not stated | Bucharest |
| Neil McKnight | Dentons | Partner | Not stated | London |
| Alex Williams | Dentons | Associate | Not stated | London |
| Sebastian Ishiguro | Dentons | Counsel | Not stated | Budapest |
| Bogdan Papandopol | Dentons | Partner | Not stated | Bucharest |
| Jakub Celiński | Dentons | Partner | Not stated | Poland |
| Paulina Galewska | Dentons | Senior associate | Not stated | Poland |
9 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- EUR 270m (approximately €270 million)
- What the figure measures
- Total transaction value
- Client
- Biofarm S.A.Target
- Counterparties
- Zakłady Farmaceutyczne Polpharma S.A. (Buy-side)
Longshield Investment Group S.A. (Sell-side)
Lion Capital S.A. (Sell-side)